Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response
| Autor: | Chien-Ting Liu, Ju-Chien Cheng, Hsueh-Ling Hsu, Kai-Yin Hsiao, Wei-Shan Hung, Ching-Ping Tseng, Po-Heng Chuang, Yu-Chiao Hsiao, Kun-Ming Rau, Wei-Ching Liu, Tzu-Min Wang, Cheng-Hsu Wang, Yu-Li Su |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment lcsh:Medicine circulating tumor cells Gastroenterology Article Targeted therapy Causes of cancer 03 medical and health sciences alpha-fetoprotein 0302 clinical medicine Circulating tumor cell Stable Disease Interquartile range Internal medicine medicine longitudinal follow-up 030304 developmental biology 0303 health sciences business.industry lcsh:R General Medicine hepatocellular carcinoma medicine.disease digestive system diseases 030220 oncology & carcinogenesis Hepatocellular carcinoma Alpha-fetoprotein business Progressive disease |
| Zdroj: | Journal of Clinical Medicine, Vol 9, Iss 1, p 188 (2020) Journal of Clinical Medicine Volume 9 Issue 1 |
| ISSN: | 2077-0383 |
| Popis: | Hepatocellular carcinoma (HCC) is among the most common causes of cancer death in men. Whether or not a longitudinal follow-up of circulating tumor cells (CTCs) before and at different time points during systemic/targeted therapy is useful for monitoring the treatment response of patients with locally advanced or metastatic HCC has been evaluated in this study. Blood samples (n = 104) were obtained from patients with locally advanced or metastatic HCC (n = 30) for the enrichment of CTCs by a negative selection method. Analysis of the blood samples from patients with defined disease status (n = 81) revealed that those with progressive disease (PD, n = 37) had significantly higher CTC counts compared to those with a partial response (PR) or stable disease (SD n = 44 for PR + SD, p = 0.0002). The median CTC count for patients with PD and for patients with PR and SD was 50 (interquartile range 21&ndash 139) and 15 (interquartile range 4&ndash 41) cells/mL of blood, respectively. A longitudinal analysis of patients (n = 17) after a series of blood collections demonstrated that a change in the CTC count correlated with the patient treatment response in most of the cases and was particularly useful for monitoring patients without elevated serum alpha-fetoprotein (AFP) levels. Sequential CTC enumeration during treatment can supplement standard medical tests and benefit the management of patients with locally advanced or metastatic HCC, in particular for the AFP-low cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |